<DOC>
	<DOCNO>NCT00813098</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , effectiveness LX1031 versus placebo control subject non-constipating irritable bowel syndrome .</brief_summary>
	<brief_title>Study LX1031 Subjects With Non-Constipating Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Males female age 1870 year old Documented diagnosis IBS ( IBSdiarrhea IBSmixed ) base upon Rome III criterion Abdominal pain/discomfort least 2 day per week screen runin period Normal structural evaluation colon within 5 year prior screen Ability provide write informed consent Inability discontinue current drug therapy IBS , except bulk agent , duration study Use anticholinergic antidepressant , opioid pain medication , drug affect bowel motility Lactose intolerance Major psychological disorder Significant nicotine caffeine use ( &gt; 10 cigarette and/or six 8 ounce cup coffee per day , respectively )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>